Ravi Viswanathan, 10% Owner at Adaptimmune Therapeutics PLC (ADAP), bought 7,142,328 shares at $1.92 ($13.7M) on 2018-03-27, disclosed to the SEC on 2018-03-28.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.90 | 571,164 | $1.1M | 7.9% |
| 2 | $1.90 | 571,164 | $1.1M | 7.9% |
| 3 | $1.92 | 6,000,000 | $11.5M | 84.1% |
| Total | $1.92 avg | 7,142,328 | $13.7M | 100% |
| Filing → |
| AVEO | BUY | 2018-07-20 | $491K | — | Filing → |
| AVEO | BUY | 2018-06-28 | $404K | — | Filing → |
| AVEO | BUY | 2018-05-30 | $591 | — | Filing → |